Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorLINARD DE GUERTECHIN, Morgane
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEZIN, Julien
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorHUCTEAU, Emilie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorJOLY, Pierre
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorGARRIGUE, Isabelle
IDREF: 12258953X
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDARTIGUES, Jean-Francois
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPARIENTE, Antoine
IDREF: 13395711X
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorHELMER, Catherine
dc.date.accessioned2022-02-09T15:28:03Z
dc.date.available2022-02-09T15:28:03Z
dc.date.created2022
dc.date.issued2022-01-07
dc.identifier.issn1758-9193en_US
dc.identifier.otherhttps://ndownloader.figstatic.com/files/32799422en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/124690
dc.description.abstractEnConsidering the growing body of evidence suggesting a potential implication of herpesviruses in the development of dementia, several authors have questioned a protective effect of antiherpetic drugs (AHDs) which may represent a new means of prevention, well tolerated and easily accessible. Subsequently, several epidemiological studies have shown a reduction in the risk of dementia in subjects treated with AHDs, but the biological plausibility of this association and the impact of potential methodological biases need to be discussed in more depth. Using a French medico-administrative database, we assessed the association between the intake of systemic AHDs and the incidence of (i) dementia, (ii) Alzheimer's disease (AD), and (iii) vascular dementia in 68,291 subjects over 65 who were followed between 2009 and 2017. Regarding potential methodological biases, Cox models were adjusted for numerous potential confounding factors (including proxies of sociodemographic status, comorbidities, and use of healthcare) and sensitivity analyses were performed in an attempt to limit the risk of indication and reverse causality biases. 9.7% of subjects (n=6642) had at least one intake of systemic AHD, and 8883 incident cases of dementia were identified. Intake of at least one systemic AHD during follow-up was significantly associated with a decreased risk of AD (aHR 0.85 95% confidence interval [0.75-0.96], p=0.009) and, to a lesser extent with respect to p values, to both dementia from any cause and vascular dementia. The association with AD remained significant in sensitivity analyses. The number of subjects with a regular intake was low and prevented us from studying its association with dementia. Taking at least one systemic AHD during follow-up was significantly associated with a 15% reduced risk of developing AD, even after taking into account several potential methodological biases. Nevertheless, the low frequency of subjects with a regular intake questions the biological plausibility of this association and highlights the limits of epidemiological data to evaluate a potential protective effect of a regular treatment by systemic AHDs on the incidence of dementia.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enHerpesvirus
dc.subject.enAlzheimer’s disease
dc.subject.enVascular dementia
dc.subject.enDementia
dc.subject.enPrevention
dc.subject.enAntiherpetic drugs
dc.subject.enInfection
dc.subject.enAntimicrobial
dc.subject.enTreatment
dc.title.enAntiherpetic drugs: a potential way to prevent Alzheimer's disease?
dc.title.alternativeAlzheimers Res Theren_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1186/s13195-021-00950-0en_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologieen_US
dc.identifier.pubmed34996520en_US
bordeaux.journalAlzheimer's Research and Therapyen_US
bordeaux.page3en_US
bordeaux.volume14en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionCNRS
bordeaux.teamACTIVE_BPHen_US
bordeaux.teamBIOSTAT_BPHen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-03563395
hal.version1
hal.date.transferred2022-02-09T15:28:08Z
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccCC BYen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Alzheimer's%20Research%20and%20Therapy&rft.date=2022-01-07&rft.volume=14&rft.issue=1&rft.spage=3&rft.epage=3&rft.eissn=1758-9193&rft.issn=1758-9193&rft.au=LINARD%20DE%20GUERTECHIN,%20Morgane&BEZIN,%20Julien&HUCTEAU,%20Emilie&JOLY,%20Pierre&GARRIGUE,%20Isabelle&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée